Upgrade to SI Premium - Free Trial

Agios Pharma (AGIO)

36.05 -1.31 (3.51%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Agios Pharma (AGIO) PT Lowered to $52 at H.C. Wainwright July 22, 2026 6:50 AM - StreetInsider Agios drops tebapivat in sickle cell after Phase 2 falls short July 21, 2026 7:00 AM - StreetInsider Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease July 21, 2026 7:00 AM - Globe NewsWire Form 4 AGIOS PHARMACEUTICALS, For: Jul 08 Filed by: Backstrom Jay T. July 10, 2026 4:18 PM - SEC Filing Agios Pharma (AGIO) PT Raised to $32 at RBC Capital July 7, 2026 7:55 AM - StreetInsider Agios Pharma (AGIO) PT Raised to $41 at Truist Securities July 7, 2026 7:08 AM - StreetInsider FDA grants priority review to Agios' mitapivat for sickle cell disease July 7, 2026 7:00 AM - StreetInsider U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease July 7, 2026 7:00 AM - Globe NewsWire Agios Pharma (AGIO) PT Raised to $46 at BofA Securities July 7, 2026 5:16 AM - StreetInsider Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: D. E. SHAW & CO, L.P. July 2, 2026 4:05 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jul 01 Filed by: Gheuens Sarah July 2, 2026 4:03 PM - SEC Filing Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah July 1, 2026 4:08 PM - SEC Filing Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET June 29, 2026 7:00 AM - Globe NewsWire Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Ballal Rahul D. June 23, 2026 5:25 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: CAPELLO JEFFREY D June 23, 2026 5:25 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Foster-Cheek Kaye I June 23, 2026 5:24 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: FOUSE JACQUALYN A June 23, 2026 5:23 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Ho Maykin June 23, 2026 5:22 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Owen Adams Catherine June 23, 2026 5:21 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Scadden David June 23, 2026 5:21 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Smith Cynthia June 23, 2026 5:19 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Viswanadhan Krishnan June 23, 2026 5:18 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Goff Brian June 23, 2026 5:18 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Burns James William June 23, 2026 5:17 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Gheuens Sarah June 23, 2026 5:16 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Jones Cecilia June 23, 2026 5:14 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Milanova Tsveta June 23, 2026 5:13 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 18 Filed by: Backstrom Jay T. June 23, 2026 5:12 PM - SEC Filing Form S-8 AGIOS PHARMACEUTICALS, June 18, 2026 4:16 PM - SEC Filing Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18 June 18, 2026 4:13 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: Owen Adams Catherine June 16, 2026 4:10 PM - SEC Filing Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: CAPELLO JEFFREY D June 16, 2026 4:08 PM - SEC Filing Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright June 15, 2026 6:49 AM - StreetInsider Agios presents Phase 3 sickle cell disease trial results at EHA conference June 13, 2026 9:00 AM - StreetInsider Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease June 13, 2026 9:00 AM - Globe NewsWire Agios Pharma (AGIO) PT Lowered to $31 at JPMorgan June 11, 2026 8:38 AM - StreetInsider Agios licenses blood disorder drug from Oscotec for $25 million upfront June 1, 2026 5:00 AM - StreetInsider Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib June 1, 2026 5:00 AM - Globe NewsWire Agios Pharma (AGIO) PT Lowered to $59 at Leerink May 29, 2026 10:42 AM - StreetInsider Agios halts tebapivat development for blood cancer indication May 29, 2026 7:00 AM - StreetInsider Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes May 29, 2026 7:00 AM - Globe NewsWire PYRUKYND gets EU approval for thalassaemia treatment May 22, 2026 10:18 AM - StreetInsider Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia May 22, 2026 10:18 AM - BizWire Agios receives European approval for PYRUKYND to treat thalassemia May 22, 2026 9:15 AM - StreetInsider Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia May 22, 2026 9:15 AM - Globe NewsWire Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC May 15, 2026 11:02 AM - SEC Filing Agios submits application for accelerated approval of mitapivat in sickle cell May 12, 2026 9:32 AM - StreetInsider Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease May 12, 2026 9:31 AM - Globe NewsWire Agios to present mitapivat data at EHA 2026 conference May 12, 2026 9:30 AM - StreetInsider Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias May 12, 2026 9:30 AM - Globe NewsWire Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: Lynx1 Capital Management LP May 6, 2026 4:22 PM - SEC Filing Agios Pharma (AGIO) PT Lowered to $36 at Truist Securities April 30, 2026 7:10 AM - StreetInsider Form SCHEDULE 13G AGIOS PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 29, 2026 4:40 PM - SEC Filing Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31 April 29, 2026 9:31 AM - SEC Filing Form 8-K AGIOS PHARMACEUTICALS, For: Apr 29 April 29, 2026 6:33 AM - SEC Filing Agios Pharma (AGIO) Tops Q1 EPS by 12c April 29, 2026 6:30 AM - StreetInsider Agios Reports First Quarter 2026 Financial Results and Provides Business Update April 29, 2026 6:30 AM - Globe NewsWire Form ARS AGIOS PHARMACEUTICALS, For: Dec 31 April 24, 2026 4:09 PM - SEC Filing Form DEFA14A AGIOS PHARMACEUTICALS, April 24, 2026 4:03 PM - SEC Filing Form DEF 14A AGIOS PHARMACEUTICALS, For: Jun 18 April 24, 2026 4:02 PM - SEC Filing Full Article List